Ascletis Pharma Inc. has announced that a petition for Post Grant Review has been filed with the United States Patent and Trademark Office by Conjupro Biotherapeutics, Inc., a subsidiary of CSPC Pharmaceutical Group Limited. The petition challenges the validity of specific claims in one of Ascletis Pharma's granted U.S. patents. The patent in question covers the molecular structure of Compound 1, which is identical to Compound 10 in CSPC's pending patent application. Ascletis had filed its patent application approximately three months before CSPC's application. The petition is currently under review by the USPTO, and its potential impact on Ascletis cannot be determined at this stage. The company will monitor developments closely and inform shareholders and investors of any significant updates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。